Christine D. Baker
Director/Board Member at TuHURA Biopharma, Inc.
Net worth: 11 504 $ as of 2024-03-30
Profile
Christine D.
Baker is a professional with a background in sales and marketing.
She is currently a Non-Executive Director at TuHURA Biopharma, Inc. Her former positions include Vice President-Sales & Marketing at Schering-Plough Corp., Vice President-Oncology at Novartis Corp., Chief Business Officer at EpicentRx, Inc., Chief Operating Officer at HOOKIPA Pharma, Inc., and Principal at Cd Baker Consulting LLC.
She holds an undergraduate degree from Dartmouth College and an MBA from Rutgers State University of New Jersey.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HOOKIPA PHARMA, INC.
0.02% | 2023-04-13 | 16,158 ( 0.02% ) | 11 504 $ | 2024-03-30 |
Christine D. Baker active positions
| Companies | Position | Start |
|---|---|---|
TuHURA Biopharma, Inc.
 TuHURA Biopharma, Inc. BiotechnologyHealth Technology TuHURA Biopharma, Inc. operates as a biotechnology company. It develops bifunctional immunoconjugates for the treatment of cancer. The company was founded in 2018 and is headquartered in Seattle,WA. | Director/Board Member | - |
Former positions of Christine D. Baker
| Companies | Position | End |
|---|---|---|
| HOOKIPA PHARMA INC. | Chief Operating Officer | 2024-01-14 |
| TYME TECHNOLOGIES, INC. | Director/Board Member | 2022-09-15 |
EpicentRx, Inc.
 EpicentRx, Inc. Pharmaceuticals: MajorHealth Technology EpicentRx, Inc. develops compounds sourced and adapted from the aerospace industry for treating cancer. Its technology includes chemical platform, RRx-001 overview, rons potential, epigenetics, collaboration and immunotherapy. The company was founded by Susan J. Knox and Mark Bednarski and is headquartered in Mountain View, CA. | Corporate Officer/Principal | 2018-12-31 |
| Cd Baker Consulting LLC | Corporate Officer/Principal | - |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Sales & Marketing | - |
Training of Christine D. Baker
| Dartmouth College | Undergraduate Degree |
| Rutgers State University of New Jersey | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| HOOKIPA PHARMA INC. | Health Technology |
| Private companies | 6 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
EpicentRx, Inc.
EpicentRx, Inc. Pharmaceuticals: MajorHealth Technology EpicentRx, Inc. develops compounds sourced and adapted from the aerospace industry for treating cancer. Its technology includes chemical platform, RRx-001 overview, rons potential, epigenetics, collaboration and immunotherapy. The company was founded by Susan J. Knox and Mark Bednarski and is headquartered in Mountain View, CA. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
TuHURA Biopharma, Inc.
TuHURA Biopharma, Inc. BiotechnologyHealth Technology TuHURA Biopharma, Inc. operates as a biotechnology company. It develops bifunctional immunoconjugates for the treatment of cancer. The company was founded in 2018 and is headquartered in Seattle,WA. | Health Technology |
| Cd Baker Consulting LLC |
- Stock Market
- Insiders
- Christine D. Baker
